Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting on June 17, 2025 (the “ Annual Meeting”). The results for the votes regarding each proposal at the Annual Meeting are set forth below. As of the record date of the Annual Meeting, April 21, 2025, there were 79,237,622 shares of the Company’s common stock outstanding. Each share of common stock entitled its holder to one vote per share. The stockholders of the Company elected three Class III directors, each to hold office until the Company’s 2028 annual meeting of stockholders or until his or her successor has been duly elected and qualified, as follows: Director For Withheld Broker Non-Votes ─────────────────────────────────────────────────────────────────────────────── Allan Jacobson, Ph. D. 60,386,986 2,122,262 4,966,822 David P. Southwell 59,200,375 3,308,873 4,966,822 Alethia Young 54,894,657 7,614,591 4,966,822 The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified by the Company’s stockholders with 67,259,475 votes “ For,” 195,233 votes “ Against,” and 21,362 votes “ Abstained.” The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders with 60,479,157 votes “ For,” 1,979,310 votes “ Against,” 44,711 votes “ Abstained,” and 4,966,822 broker non-votes. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: June 17, 2025 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer